Small-cap radiation oncology company Accuray (NASDAQ:ARAY) has been struggling for a while now. Despite compelling technology that is superior to that of much larger rivals Varian (NYSE:VAR) and Elekta (OTCPK:EKTAY) in at least some significant respects, Accuray's operational missteps have sent the stock down almost 20% over the past year and almost 45% over the past five years, making it a significant underperformer.
With that underperformance making the shareholders restless, a change in management followed and Josh Levine took the helm. It's really too soon to expect a big impact from Levine's new direction and strategic priorities, and the early results have been mixed. Even so, a big sequential rebound in orders gives investors...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|